Compare Expedia Group Inc (EXPE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Recursion Pharmaceuticals Inc — how do they compare? Expedia Group Inc trades at $269.06 (market cap $32.42B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: Expedia Group Inc is far larger — about 15.1× Recursion Pharmaceuticals Inc's market cap, and Expedia Group Inc pays a 0.71% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EXPE | RXRX | |
|---|---|---|
Market Cap | $32.42B | $2.14B |
Volume | 1,940,671 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $6.79 |
52-Week Low | $188.51 | $2.84 |
Typical Hold Time | 48 Days | 22 Days |
Enterprise Value | $30.98B | $1.66B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, amid a bearish technical signal and recent news-driven volatility. The stock shows strong fundamentals with consistent earnings beats, revenue growth to $14.73B in 2025, and robust profitability margins. Recent layoffs and competitive threats from AI travel agents have pressured sentiment, but analyst consensus remains largely positive with a $335.06 price target.
The outlook balances solid financial health and attractive valuation against near-term competitive and execution risks. Upside potential exists if Expedia navigates AI disruption and sustains booking growth, but investor caution is warranted given technical weakness and industry headwinds.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
